Most guidelines for the management of patients with cardiovascular disease recommend angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas angiotensin receptor blockers (ARBs) are merely considered an alternative for ACE inhibitor-intolerant patients. The aim of this review was to compare outcomes and adverse events between ACE inhibitors and ARBs in patients. In patients with hypertension and hypertension with compelling indications, we found no difference in efficacy between ARBs and ACE inhibitors with regard to the surrogate endpoint of blood pressure and outcomes of all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. However, ACE inhibitors remain associated with cough and a very low risk of angioedema and fatalities. Overall withdrawal rates because of adverse events are lower with ARBs than with ACE inhibitors. Given the equal outcome efficacy but fewer adverse events with ARBs, risk-to-benefit analysis in aggregate indicates that at present there is little, if any, reason to use ACE inhibitors for the treatment of hypertension or its compelling indications. (J Am Coll Cardiol 2018;71:1474-82)
The human understanding, once it has adopted opinions, either because they were already accepted and believed, or because it likes them, draws everything else to support and agree with them. And though it may meet a greater number and weight of contrary instances, it will, with great and harmful prejudice, ignore or condemn or exclude them by introducing some distinction, in order that the authority of those earlier assumptions may remain intact and unharmed.
-Francis Bacon, Novum Organum, 1620 (1) E ver since captopril, the first angiotensinconverting enzyme (ACE) inhibitor, became available in 1981, this drug class has been extensively used in a variety of cardiovascular (CV) diseases. Losartan, the first angiotensin receptor blocker (ARB), was launched in 1995, more than a dozen years after the introduction of the ACE inhibitor captopril. Both ACE inhibitors and ARBs are commonly used in patients with hypertension, heart failure, coronary artery disease, diabetes, and chronic kidney disease (CKD). However, many American and European guidelines for the management of patients with CV disease recommended ACE inhibitors as a first-choice therapy, whereas ARBs were merely considered alternative therapy for ACE inhibitor-intolerant patients.
In the following review, we compare the efficacy and safety of the 2 drug classes (which are now mostly generic) for the treatment of hypertension and hypertension associated with what has been called compelling indications.
MECHANISM OF ACTION
The mechanism of action of ACE inhibitors and ARBs Messerli et al.
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A P R I L 3 , 2 0 1 8 : 1 4 7 4 -8 2 P a t i e n t s w i t h h e a r t f a i l u r e . In contrast to hypertension, in heart failure ACE inhibitors and ARBs have been compared with placebo in multiple clinical tri-
als. CONSENSUS (Cooperative North Scandinavian
Enalapril Survival Study) (25) showed an impressive 31% reduction in mortality at 1 year in patients with severe heart failure who were treated with enalapril when compared with placebo. In the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) trial program, candesartan was either added to ACE inhibitors (CHARM-Added) (26) or substituted when ACE inhibitors were not tolerated (CHARM-Alternative) (27) . In both trials candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for heart failure.
A recent network meta-analysis showed that treatment with ACE inhibitors, ARBs, beta-blockers, mineralocorticoid antagonists, and angiotensin receptor-neprilysin inhibitor and their combinations were better than treatment with placebo in reducing all-cause mortality rates (28) . In comparison with placebo, ACE inhibitor use was associated with a 16% reduction in mortality, whereas the combination of ACE inhibitors, beta-blockers, and mineralocorticoid antagonists was associated with a 56% reduction in mortality compared with placebo (28) . ACE inhibitorbased therapy was superior to placebo for all-cause mortality, whereas ARB-based therapy was not.
However, the data on ACE inhibitors versus placebo (32) . These investigators reported that ACE inhibitors also reduced the risk for all-cause mortality and were possibly superior to ARBs for kidney failure, CV death, and all-cause mortality in patients with CKD. However, a closer look at their data clearly showed that the differences between ARBs and ACE inhibitors were not statistically significant. In the REACH cohort, ARBs were superior to ACE inhibitors in reducing the primary outcome even in patients with an estimated glomerular filtration rate >30 ml/min/1.73 m 2 (19 
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COST AND PRACTICAL CONSIDERATIONS
In the past, the main argument against using ARBs was that they were not available in a generic (8) withdrawal rates of ARBs were 32% lower than with placebo merely reflects the fact that hypertensive CV 
